核苷酸转运体表达与吉西他滨治疗胰腺癌患者临床疗效相关性的研究进展

Nucleoside Transport Expression Associated with Clinical Response of Gemcitabine in Pancreatic Cancer

关键词:  吉西他滨  胰腺癌  核苷酸转运体  基因多态性  临床疗效  不良反应

Key words:  gemcitabine  pancreatic cancer  nucleoside transport  single nuelsoside polymorphisms  clinical response  adverse effect

摘要:

目的 探讨核苷酸转运体表达与吉西他滨抗胰腺癌临床疗效相关性的研究进展。方法 通过查阅国内外文献，对相关研究归纳、总结进行综述。结果 吉西他滨是胰腺癌化疗的一线药物，较大个体化差异和有效率偏低是目前临床应用的挑战，核苷酸转运体是吉西他滨摄取入细胞的内吞转运体，它的蛋白或mRNA表达可能与接受吉西他滨治疗胰腺癌患者的临床疗效和不良反应相关，但尚未达成共识。结论 核苷酸转运体表达与吉西他滨抗胰腺癌临床疗效的相关性还需要进一步研究，为吉西他滨在胰腺癌中实现临床个体化治疗提供参考依据。

Abstract:

OBJECTIVE To introduce the research progress on the nucleoside transport expression associated with clinical response in pancreatic cancer who treated with gemcitabine. METHODS The domestic and international articles were reviewed to summarize the relevant studies. RESULTS Gemcitabine is the first-line Chemotherapeutic agent for treatment of pancreatic cancer, but high interpatient variability and low response rate has been the major challenge faced by clinicians, Cellular uptake of gemcitabine is mediated by nucleoside transporters,expression (including protein and mRNA) of nucleoside transport may be associated with clinical response and adverse effect in pancreatic cancer, who were treated with gemcitabine. but it has not reach the consensus in clinic. CONCLUSION The future study will fouce on nucleoside transport expression associated with clinical response of gemcitabine in pancreatic cancer, provided the basis on presonalized treatetment option for pancreatic cancer patients.